Vivjoa™ (oteseconazole capsules – Mycovia Pharmaceuticals) has received FDA approval to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females who have a history of RVVC and are not of reproductive potential.

• RVVC is also known as chronic yeast infection and defined by the S. Centers for Disease Control as three or more symptomatic acute episodes of yeast infection within 12 months. Vivjoa is the first medication FDA approved specifically for treatment of RVVC.
• Vivjoa is taken by mouth with Recommended dosing is as follows:
  • Treatment with Vivjoa ONLY: Administer 600mg on Day 1 and 450mg on Day Beginning on Day 14, administer 150mg once every seven days for 11 weeks.
  • Treatment with Vivjoa and fluconazole: Administer fluconazole 150mg by mouth on Days 1, 4, and On Days 14 through 20, administer Vivjoa 150mg once daily. Beginning on Day 28, administer Vivjoa 150mg once every seven days for 11 weeks.
• Launch and pricing information are not available.